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Human immunodeficiency virus type 1 mRNA expression in
peripheral blood cells predicts disease progression
independently of the numbers of CD4+ lymphocytes
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ABSTRACT To address the sigficanOe f human lmmu-
nodeficlency virus (HIV) replication in periphrl blood mono-
nuclear cells (PBMCs), we. have used reverse trascriptase-
initiated PCR to meue HV-1 mRNA epession in PBMC
speclmens collected from a cohort of HIV-infected Individuals
during a long-term spective study. We found dramatic
differences in HIV mRNA among individuals with
very similar clinical and lbora Indices, and this variation
stronly correlated with the future course of the disease. No
evidence of viral was detected in PBMCs from
tic indivlU wlswho, theater, had normal evels of
CD4+ cells for at least 5 years. Irrespective of whether the
CD4+ cell numers were normal at the tme of i,
abundant expr on of HIV-1 mRNA in PBMCs id
acelerated doisep n within the next 2 years. Thus,
independently of what may be the rate of H1IV Lotion i
other viral reserv such as lymphatic tissue, the amount of
HIV mRNA in PBMCs appears to reflect the subsequent
development of HIV disease. We have also used the reverse
scriptase-initated PCR may to demonstrate a trasent
response to 3'-azdo-3'oxhmdine treatment. Detmina-
tieo of HV-1 MRNA e in the PBMCs of infected
individuals could, therefore, have nt clinical utility as
a prg t in ato nd as a means to ging and moni-
toring antiviral therapies.
The pathogenesis of human immunodeficiency virus (HIV)
type 1 infection is characterized by a variable but often
prolonged asymptomatic period after the acute viremic phase
(1). Previous work has established a correlation between HIV
disease progression and increasing amounts of infectious
virus, viral antigens, and virus-specific nucleic acids (2-12).
However, HIV mRNA, indicative of viral replication, has
been demonstrated in cells at all stages of the disease, and it
has been suggested that true microbiological latency at the
cellular level may, therefore, not exist (8, 12). In particular,
active viral replication may occur in the lymphatic tissue
throughout the clinically latent period (9, 13-15).
Previous studies examining HIV replication in peripheral
blood mnononuclear cells (PBMCs) of infected individuals
have, however, not addressed the critical issue of whether
the differences in HIV mRNA levels correlate with the
subsequent course of the disease. By examinig HIV mRNA
expression in serial cryopreserved PBMC samples from
clinically well-characterized HIV-infected individuals col-
lected over a 7-year period, we found that the rate of viral
replication in PBMCs correlates well with the subsequent
clinical course of the infection. We also examined the repli-
cation of HIV in PBMCs during antiretroviral therapy and
found a significant but transient decrease in HIV-1 mRNA
expression when 3'-azido-3'-deoxythymidine (AZT) therapy
was initiated during the study.
MATERIALS AND METHODS
Cryopreserved Ficoll/Hypaque-purified PBMC samples
were thawed, washed with phosphate-buffered saline solu-
tion, and subjected to RNA extraction using the gnidium
isothiocyanate/acid phenol method (16). In addition to in-
formation in Fig. 1, a detailed description of the reverse
transcriptase-initiated PCR (RT-PCR) and the sequences of
the primers has been provided (17). After gel electrophoresis
and autoradiography, the intensities of the multiply-spliced
(MS) HIV and unspliced (US) HIV signals were compared
with those of the control RNAs analyzed in jarallel to
estimate the approximate amounts of HIV-specific mRNAs
present in the patient PBMC samples.
RESULTS
To examine HIV replication inPBMC samples, we developed
RT-PCR assays specific for US and MS HIV mRNA as well
as cellular (-actin mRNA (Fig. 1A). US HIV RNA gives rise
to Gag-Pol polyprotein and is also packaged in virions as
genomic HIV RNA. MS HIV mRNAs encode regulatory
HIV proteins such as Tat and Rev and are not present in
virions in significant amounts (K.S. and D.B., unpublished
data), thus representing a good measure of ongoing viral
replication in situ. The RT-PCR ofPBMC RNA samples was
initiated by a step of random-primed cDNA synthesis fol-
lowed by specific amplification ofdiagnosticDNA fragments
in the presence of a radiolabeled nucleotide. The PCR
products were then analyzed by gel electrophoresis and
visualized by autoradiography. To estimate the number of
HIV mRNA molecules in the patient samples and to confirm
their quantitative amplification after reverse transcription,
we prepared control samples by serially diluting known
amounts of corresponding in vitro-transcribed HIV RNAs
into a constant amount of PBMC RNA prepared from an
HIV-negative donor. Fig. 1B shows a typical result of an
RT-PCR analysis of these control RNAs. To control for the
amount and integrity of the RNAs prepared from different
PBMC samples, as well as the uniform efficiency of their
reverse transcription, a (3-actin mRNA-specific fragment was
also amplified from every cDNA preparation. Variation in the
reverse transcription step between the various gene-specific
PCR assays was minimized since our assay was based on
random-primed reverse transcription, thus allowing the US
Abbreviations: HIV, human immunodeficiency virus; RT-PCR,
reverse transcriptase-initiated PCR; PBMC, peripheral blood mono-
nuclear cell; AZT, 3'-azido-3'-deoxythymidine (zidovudine); US,
unspliced; MS, multiply spliced; NYBC, New York Blood Center.
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HIV, MS HIV, and 3-actin mRNAs to be amplified from a
single cDNA preparation.
This assay was used to quantitate US and MS HIV mRNA
in serial cryopreserved PBMC samples collected from indi-
viduals involved in a long-term prospective study at the New
York Blood Center (NYBC). The NYBC cohort includes 362
HIV-1-seropositive gay men who entered the study in 1984,
148 ofwhom had been followed since the late 1970s as a part
ofa hepatitis B study, allowing timing of seroconversion in 41
patients. Among these 362 men, 224 developed a disease
meeting the CDC 1992 criteria for AIDS. Ofthe remaining, 79
men had evidence of immune deficiency (<500 CD4+ cells
per mm3) but did not develop AIDS, and 59 retained normal
CD4+ cell numbers throughout the study.
The present study was prompted by our initial examination of
a small number of PBMC samples from individuals who expe-
rienced different clinical courses of HIV infection. It revealed
abundant HIVmRNA expression in samples from patients with
an advanced disease, whereas a large variation was observed in
samples from asymptomatic individuals (unpublished data). To
address the significance of this variation, 18 individuals were
selected from the NYBC cohort, all of whom were initially
asymptomatic and had very similar clinical and laboratory
indices but whose future course of disease during the subse-
quent years offollow-up fell into two contrasting patterns (Table
1 and Fig. 2A). All 18 individuals included in the study contin-
ued to have normal numbers of CD4+ cells during the first 3
years of the follow-up at NYBC. Thereafter 7 ofthem (patients
A-G, group I) developed CD4+ lymphocytopenia and AIDS,
whereas the other 11 (patients H-R, group II) continued to have
normal CD4+ cell levels and were still asymptomatic when the
study was discontinued in 1991.
The first samples from each individual, from which their
HIV gene expression pattern was established, were always
analyzed in a blinded manner, such that the clinical data were
disclosed only after the RT-PCR results were documented.
Additional samples from each individual were then examined
to define in more detail the temporal aspects of HIV mRNA
expression over the years. Fig. 2B shows the results from
RT-PCR assays of representative PBMC specimens from
the 14 individuals included in Fig. 2A, while the entire data
base of RT-PCR results is summarized in Table 1. These
data reveal a strong correlation between HIV replication in
PBMCs and the future clinical course ofHIV infection. None
of the samples from individuals who continued to have
normal numbers ofCD4+ cells during the subsequent 5 years
(patients H-R) expressed a detectable amount of MS HIV-1
mRNA that would indicate viral replication in these cells
(Table 1 and Fig. 2B). In two cases (patients K and N), a faint
FIG. 1. HIV-1 RT-PCR assay. (A) Schematic
outline of HIV-1 structure illustrating the relevant
viral genes and features of HIV-1 RNA mRNA
splicing. The arrows indicate the location of the
PCR primers chosen based on maximal HIV-1
sequence conservation arnd empirical evaluation for
optimal performance in RT-PCR. (B) RT-PCR
analysis of in vitro-transcribed HIV-1 RNAs diluted
in indicated amounts into a constant amount (1 pg)
of total PBMC RNA from a HIV-negative donor.
One femtogram (fg) of each control HIV RNA
corresponds approximately to 4 x 103 copies of
these molecules. A uniform efficiency of reverse
transcription among the cDNA reactions is indi-
cated by the comparable intensities of the PBMC-
derived 13-actin mRNA signals.
US mRNA but no MS HIV signal, was detectable after long
autoradiographic exposures (data not shown). Expression of
both US and MS HIV-1 RNA was readily detected in all
PBMC specimens collected from individuals whose number
of CD4+ cells, thereafter, declined below 500 cells per mm3
within 2 years of sampling. Abundant expression of either
HIV mRNA species (Table 1) appeared predictive of active
disease progression and was in every case followed by a
significant drop in the number of CD4+ cells during the next
1 or 2 years. Thus, as illustrated in Fig. 2, HIV replication in
blood cells does not strictly correlate with the clinical stage
ofHIV infection. Rather, dramatic differences in HIV mRNA
expression levels between individuals in the asymptomatic
phase of the infection were observed, and this variation
strongly correlated with the clinical course of their disease
over the subsequent 1-3 years.
As expected, abundant expression of both US and MS
HIV-1 mRNA was observed in most samples from individ-
uals with decreased CD4+ cells or AIDS (Table 1). When
patients became extensively CD4+ lymphocytopenic, a rel-
ative loss of MS HIV-1 mRNA expression was observed,
while expression of US mRNA still remained high (e.g.,
individual C). Cell culture studies have indicated that MS
HIV-1 mRNA is predominantly expressed early after HIV
infection (18, 19). Thus, the low levels ofMS HIV mRNA in
some PBMC samples probably reflects inefficient viral
spread due to few remaining susceptible uninfected target
cells. Also, some of the intense US HIV RT-PCR signal in
such samples may be derived from genomic RNA of virions
associated with the PBMCs rather than from US HIV mRNA
produced in these cells.
To study the effects of antiretroviral therapy on viral
replication in PBMCs and to test the possibility that the US
and MS HIV mRNA species would be derived from cells with
substantially different turnover rates, we also focused on
samples collected shortly before and after the initiation of
AZT therapy. For this purpose, in addition to the 18 originally
selected individuals included in Table 1, serial samples from
3 other AZT-treated individuals were also analyzed (Fig. 3).
When AZT treatment was initiated in the interval between
the collection of two PBMC samples, a significant decrease
in HIV expression was usually observed (Table 1 and Fig. 3).
Little or no effect on HIV mRNA expression was seen in one
case, probably because AZT was initiated 4 months before
the first post-AZT sample was obtained (Table 1, patient D).
Despite continuous antiviral therapy, the favorable effect of
AZT was typically lost within 4-6 months after treatment
initiation. These results correlate with the limited benefit of
AZT in the treatment of HIV infection (20) and suggest that
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Table 1. Summary of the RT-PCR analyses of HIV-1 mRNA expression in sequential PBMC samples from 18 HIV-infected individuals
during a 7-year follow-up period
CD4+ HIV mRNA
cells,
ID Date no. US MS
CD4+ HIV mRNA
cells,
ID Date no. US MS
CD4+ HIV mRNA
cells,
ID Date no. US MS
Disease progression after an asymptomatic period with normal numbers of CD4+ cells
A 01/30/85 914 ++
01/19/87 1050 +++
09/20/87 645 + +
01/24/88 972 +
06/15/88 72 +++
10/16/88* 99 - ++
02/26/89 43 + + +
11/19/89 24 +++
SC c 10/84 AZT 10/84
B 09/10/84 1691 +
01/28/85 950 +
02/18/86 732 +
01/07/87 793 + +
10/26/87 798 + +
04/19/88 598 ++
07/25/88 263 +++
09/06/88 258 + + +
03/13/89* 194 +
07/24/89 136 + +
04/16/90 39 ++
03/12/91 21 +++
SC < 4/84 AZT 01/13/89
H 12/17/84 1335 -
02/03/88 997 -
02/06/91 1080 -
SC < 3/84
I 08/06/84 1089 -
09/09/85 1573 -
02/04/91 623 -
SC s 3/84
J 01/29/85 1042 -
09/23/85 783 -
09/09/91 1137 -
SC c 4/84
K 10/15/84 830 +
08/07/85 1378 -
02/06/91 544 + +
SC < 1979
+ C 02/27/85 881 + -
++ 06/10/86 713 + +
+ 03/11/87 909 + +
++ 07/21/87 755 + ++
++ 07/24/88 572 + +
+ 09/25/88 703 +++ ++
+ 11/29/88 152 ++ ++
+ 04/09/89* 98 + +
10/01/89 29 ++ +
05/22/90 2 +++ -
+++ SC 8-10/84 AZT 01/28/89
++
+
++
++
+
+
+
D 08/07/84 1076 + +
04/30/85 1480 + +
09/01/87 986 + +
05/31/88 920 +++ +++
02/14/89 457 +++ ++
07/31/90* 385 +++ ++
04/23/91 35 +++ +
SC < 06/80 AZT 04/01/89
No apparent disease progression during the study
_ L 09/11/84 1034 -
- 06/04/85 1493 -
- 01/29/91 894 +
SC < 3/79
+
- M 08/12/84 1266 - -
- 04/21/85 1287 - -
- 04/17/91 975 - -
SC ' 3/79
- N 07/31/84 817 + -
- 08/27/85 952 + -
- 08/06/91 1159 ND ND
SC 5 4/79
- 0 02/04/85 733 - -
- 04/01/86 1173 - -
+ 01/27/91 548 - -
04/08/92 694 ND ND
SC 5 5/89
E 08/12/84 998 +
03/23/86 678 +
04/26/87 1039 +
01/24/88 725 ++
06/12/88 441 +
11/13/88 461 +++
06/18/89 345 ++++
SC < 3/83
F 09/04/84 728 +
07/27/86 660 +
11/02/88 598 ++
04/16/91 188 +++
SC < 1979
G 12/17/84 1122 +
03/11/86 969 +
07/06/86 665 +
04/27/87 1199 +
10/09/88 610 +
02/19/89 252 +++
04/09/89 117 ++
11/12/89* 92 ++
08/05/90 54 ++
SC s 3/38 AZT 09/12/89
P 11/05/84 1293
07/31/85 1320
08/06/91 1016
SC 2-5/80
Q 01/29/85 1458
03/06/88 1955
10/08/91 1418
SC c 5/84
+ +
R 06/17/85 759 -
05/07/90 468 -
04/06/91 607 ND
SC 8/84-1/85
US and MS HIV-1 mRNA as well as cellular P-actin mRNAs were measured Erom each sample as described in Fig. 1. +++ +, Amount of
HIV mRNA corresponding to >1 x 105 copies of in vitro-transcribed control RNA molecules per pg of PBMC RNA; + + +, 0.2-1 x 105; + +,
0.5-2 x 104; +, 1-5 x 103; -, <1 x 103 copies. The date and the CD4+ cell number at the time of sampling are shown. In three patients (patients
N, 0, and R), an additional CD4+ measurement is shown to illustrate the subsequent course of the disease even if HIV mRNA expression was
not determined (ND). SC denotes the approximate time when, or before which (<), seroconversion occurred. When applicable, the date when
AZT treatment was initiated is shown, and the first post-AZT specimen is marked with an asterisk (*). ID, patient identification.
determination of HIV-1 mRNA expression in PBMCs could
be useful in directly evaluating the effects of antiretroviral
therapies and in monitoring the subsequent emergence of
drug-resistant virus replication.
The decreased HIV-1 expression after the initiation ofAZT
therapy also suggests that both US and MS HIV mRNA
species are derived from cells with a relatively rapid turnover
rate. In contrast to a previous report (21), we found no
evidence of latently infected cells expressing abundant MS
HIV-1 mRNA but no US HIV-1 mRNA. Rather, any detect-
able MS HIV mRNA in PBMCs appeared to be incompatible
with a long-term (5 years) maintenance of normal levels of
CD4+ cells. The absence of MS HIV mRNA, however, did
not always indicate that an individual would remain progres-
sion-free, because early samples from certain individuals
who later experienced disease progression were also found to
be negative (patients C, E, and F). Also, readily detectable
expression of both US and MS HIV mRNA was observed in
recent samples from 3 of the 11 long-term asymptomatic
individuals (patients K, L, and Q), suggesting eventual acti-
vation oftheir disease. Nevertheless, lack ofMS HIVmRNA
correlated in all cases with a benign proximal course of the
++
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+
+
ND
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FIG. 2. (A) CD4+ cell measurements of 14 individuals during a 7-year follow-up shown on a semilogarithmic scale. The alphabetical codes
correspond to those in Table 1. (B) RT-PCR analysis of US HIV-1, MS HIV-1 mRNA, and cellular P-actin mRNA in PBMC samples from the
14 individuals included in A. Each sample was collected at a time when CD4+ cell numbers were normal, as indicated in the parentheses above
the corresponding lanes of the gel.
disease: the time between the last sample negative for MS
HIV-1 mRNA and the first CD4+ measurement <500 cells
per mm3 was never <2 years and often much longer.
DISCUSSION
The present data show that increased expression of HIV
mRNA in PBMCs substantially precedes clinically defined
progression of the disease. To our knowledge, longitudinal
study addressing the rate of HIV replication in PBMCs has
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FIG. 3. HIV-1 mRNA expression in sequential PBMC samples
from four patients obtained before and after initiation of AZT
therapy. As indicated, AZT treatment was started between the
collection of the first and the second sample. The dates of sampling
and the corresponding measurements of CD4+ cells are also shown.
The second panel from the left corresponds to patient B in Table 1.
not been previously reported, but results from two studies
quantitating viral load during HIV infection are available (4,
11). Both ofthese studies reported a correlation between viral
load and the current disease status but suggested that an
increase in viral load could also precede clinical progression
of the disease. Viral load in an infected individual is deter-
mined by the opposing effects of viral replication and removal
of productively infected cells and cell-free HIV. Thus, active
HIV replication could occur for long times without an ac-
companying increase in the overall viral load.
Our results define a distinct period late in the asymptom-
atic phase of HIV infection that is characterized by active
viral replication in the blood cells in the absence of apparent
signs of the immune system destruction. Identification of
such a phase of subclinical disease progression may help to
characterize the pathogenic process by which HIV infection
leads to immunodeficiency and also could have important
therapeutic implications.
The underlying causes that activate HIV replication in
PBMCs remain unclear. Also, whether the low (undetect-
able) level of viral mRNA expression observed in the blood
cells ofsome long-term asymptomatic individuals is due more
to a particularly effective anti-HIV immune response than to
a lower replicative potential of the virus in these individuals
remains an important question. The relation of the present
findings to the recently recognized active infection in the
lymphatic tissues ofasymptomatic individuals with little viral
replication in their PBMCs (9) is yet another issue that needs
to be addressed. It has been suggested that active viral
replication in PBMCs would indicate that significant damage
in the lymphatic tissues has already occurred (1).
In contrast to the conclusions of an earlier study (21), we
found no correlation between a specific HIV mRNA splicing
pattern and clinical latency of HIV infection. Exchange of
materials with the investigators of that study has revealed
that this is due to differences in the performance of the two
RT-PCR techniques, particularly the higher sensitivity ofthe
current assay for US HIV-1 RNA (data not shown). Thus, we
do not presently believe that long-lived latently infected cells
expressing some (MS) but not all (US) HIV mRNA species
A
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represent a significant viral reservoir in asymptomatic HIV-
infected individuals.
Previous studies (3, 8, 9) suggested that viral mRNA can be
readily detected in the PBMCs of most, if not all, infected
individuals. However, by selecting a population including
many individuals who remained progression-free for several
years, we found that many PBMC specimens from HIV-
infected individuals have no apparent expression of HIV
mRNA. Unlike the material examined by us, a panel of
PBMC samples from a randomly selected group of HIV-
infected individuals would be expected to include few rela-
tively early samples from such long-term asymptomatic in-
dividuals. However, it cannot be ruled out that the sensitivity
of an RT-PCR assay used in other studies could be greater.
Therefore, it is important to point out that the threshold of
detection of HIV mRNAs is not crucial to the present
conclusions, as they are derived from ratios of signals at
various times of sampling.
Besides their implications for the pathogenic process of
HIV infection, our data also suggest that quantitation ofHIV
mRNA in PBMCs could have significant clinical utility as a
prognostic indicator. The HIV RT-PCR assay was found to
reliably distinguish individuals who have otherwise identical
laboratory and clinical indices but who will subsequently
experience contrasting clinical courses ofinfection. Based on
our data, it is safe to conclude that, independently of the
current CD4+ cell numbers, the prognosis for the next 3 years
of an individual with undetectable levels of PBMC HIV
mRNA differs dramatically from that of an individual show-
ing abundant HIV mRNA expression. We believe that such
prognostic information would already be clinically valuable,
for example, in examining individuals involved in trials
testing antiretroviral therapies, and perhaps in the future, in
optimal targeting of such therapies. To establish the value of
this approach as a widely used screening test, additional work
needs to be done.
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